Jazz Pharmaceuticals stock reports record Q2 revenue growth

Jazz Pharmaceuticals stock was trading at USD 233.58 on Nasdaq on September 24, 2026, down 0.55 percent and 12.31 percent below its 52-week high of USD 266.38. The company is combining record quarterly growth with a larger development pipeline after its Actio Biosciences acquisition.

Revenue reaches USD 1.2083 billion

Jazz reported Q2 2026 revenue of USD 1.2083 billion, up 16 percent from Q2 2025, according to Stock Titan. The result gives the company a larger base for the second half, with growth spread across sleep, epilepsy and oncology products.

Q2 adjusted EPS came in at USD 5.71 against a consensus estimate of USD 6.04, while acquired in-process research and development expenses reduced adjusted EPS by USD 0.94, according to Zacks. The contrast matters: operating growth was strong, but acquisition-related costs weighed on the quarter's adjusted profitability.

Guidance rises to USD 4.75 billion

Jazz raised its full-year 2026 revenue guidance to USD 4.60 billion to USD 4.75 billion from USD 4.25 billion to USD 4.50 billion, as reported by Yahoo Finance. The upper end is USD 250 million above the former upper end, a 5.56 percent increase that raises the importance of execution in the sleep franchise.

Actio expands the pipeline

On September 15, 2026, Jazz completed its acquisition of Actio Biosciences for USD 820 million upfront, according to the company release. The transaction adds Actio's epilepsy candidate ABS-1230 and extends Jazz's development pipeline beyond its marketed portfolio.

Stock stays below yearly high

Jazz Pharmaceuticals stock stood at USD 233.58 in Nasdaq trading on September 24, 2026, with a market capitalization of USD 14,672,935,008. Its 52-week range is USD 125.79 to USD 266.38, leaving the current quote 85.73 percent above the low and 12.31 percent below the high.